Press Releases
-
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
-
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
-
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Spotlight
The Complexities of Gene Therapy Manufacturing
Learn more about what goes into manufacturing gene therapies and Sarepta’s approach to meeting the challenges inherent in making these transformative therapies a reality for patients with rare diseases.
Highlights
Our FDA-Approved Treatments
Learn more about our FDA-approved treatments.
A Day in The Life at Sarepta
Hear from employees and how our mission drives their work.
